Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy

• Status: Unknown status
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this prospective, randomized, controlled study is to investigate the effect of pretreatment with intravenous Alprostadil on the incidence of CIN in a high-risk population of patients with both type 2 diabetes mellitus (T2DM) and CKD undergoing coronary angiography, and evaluate the influence of such potential benefit on short-term outcome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Shanghai 10th People's Hospital
• Treatments: Alprostadil

Criteria

Inclusion Criteria:

• Patient that underwent coronary angiography

• T2DM

• CKD stages 2 and 3, eGFR 30 to 89ml/min per 1.73m2

• Alprostadil naive, or not on Alprostadil treatment for at least 14 days

• Withdrawal metformin or aminophylline for 48h before angiography

Exclusion Criteria:

• serum Cr. More than 3 mg/dl

• electrolyte and acid-base imbalance

• pulmonary edema

• allergy to Alprostadil